)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
AIM ImmunoTech (AIM) investor relations material
AIM ImmunoTech Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Net loss for Q2 2025 was $2.8M, up 52% year-over-year, mainly due to lower interest income and revenue, partially offset by reduced G&A expenses and lower warrant valuation loss.
Six-month net loss decreased 15% year-over-year to $6.5M, driven by lower G&A and R&D expenses, despite a drop in revenue and interest income.
Ampligen clinical programs in pancreatic cancer and post-COVID fatigue advanced, with positive safety and efficacy updates in ongoing trials.
Company effected a 1-for-100 reverse stock split in June 2025 to regain NYSE compliance; trading was reinstated after a temporary suspension.
Financial highlights
Q2 2025 revenue was $25K, down from $50K in Q2 2024, due to lower patient participation in the Ampligen Cost Recovery Program.
Operating loss for Q2 2025 was $2.65M, compared to $3.69M in Q2 2024.
Cash and equivalents at June 30, 2025, were $476K, with marketable investments of $359K, down from $1.7M and $2.3M at year-end 2024.
Stockholders' deficit widened to $6.5M at June 30, 2025, from $1.3M at December 31, 2024.
Net cash used in operations for the first half of 2025 was $3.9M, a significant improvement from $7.8M in the prior year period.
Outlook and guidance
Management highlights substantial doubt about the ability to continue as a going concern due to recurring losses, working capital deficit, and stockholders' equity below NYSE listing requirements.
Additional funding is required to support ongoing operations and clinical trials; recent $8M financing closed in July 2025.
Company is prioritizing clinical development in pancreatic cancer and post-COVID fatigue, with plans for further trials and regulatory engagement.
Assess Ampligen's commercial prospects in Argentina.
Explain the hold on AMP-270 clinical trial.
Discuss the implications of the 2025 S-1 financing.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma, Inc., is an immuno-pharmaceutical company dedicated to the research and development of therapeutics for the treatment of multiple types of cancers, viral diseases, and immune-deficiency disorders. The company's leading product candidate is Ampligen, a drug composed of macromolecular ribonucleic acid molecules aimed at treating chronic fatigue syndrome (CFS). Ampligen is also under development for various cancer types, including renal cell carcinoma, malignant melanoma, and others, as well as for conditions like Hepatitis B, HIV, COVID-19, and post-COVID conditions. Another key product is Alferon N Injection, an injectable formulation of natural alpha interferon for treating human papillomavirus (HPV) and genital warts. The company is headquartered in Ocala, Florida, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage